title: [A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis].
abstract: OBJECTIVE
  This study was done to evaluate the efficacy of rabeprazole (proton-pump-inhibitor) and ranitidine (H(2)-receptor antagonist) in the symptom relief and treatment of erosive esophagitis diagnosed by endoscopy.
  
  
  METHODS
  A total of 110 patients with typical gastroesophageal reflux disease (GERD) symptoms were enrolled in this multicenter study. They were randomized into rabeprazole group (53 patients) and ranitidine group (57 patients) respectively. The patients in rabeprazole group were given 10 mg of rabeprazole and ranitidine group received 300 mg of ranitidine before breakfast and dinner for 8 weeks. After the end of treatment, we evaluated the endoscopic healing rate of reflux esophagitis and symptomatic improvement.
  
  
  RESULTS
  After 8 weeks of treatment, rabeprazole group showed significantly higher complete endoscopic cure rate than ranitidine group (86.8% [46/53] vs. 57.9% [33/57], p=0.001) and higher symptomatic improvement of heartburn (91.2% [31/34] vs. 76.2% [32/42], p=0.085), especially in the first 7 days (76.7% vs. 45.3%, p=0.008). Also, rabeprazole group showed significantly higher improvement of regurgitation symptom than ranitidine group (100% [35/35] vs. 83% [39/47], p=0.009). Both group showed no differences in the improvement of chest pain and globus sensation. All the adverse events (rabeprazole group 4 events vs. ranitidine group 3 events) were mild and there was no abnormality in laboratory test.
  
  
  CONCLUSIONS
  In patients with GERD, rabeprazole 10 mg b.i.d. is superior to ranitidine 300 mg b.i.d. in healing of reflux esophagitis and resolving typical GERD symptoms. Rabeprazole is an effective and well-tolerated drug for GERD treatment.
authors.affiliation: Department of Internal Medicine, Chungnam National University College of Medicine, Chungnam, Korea. jeonghy@cnu.ac.kr
authors.forename: Hyun Yong
authors.initials: HY
authors.lastname: Jeong
authors.forename: Byong Seok
authors.initials: BS
authors.lastname: Lee
authors.forename: Jae Kyu
authors.initials: JK
authors.lastname: Sung
authors.forename: Tae Yong
authors.initials: TY
authors.lastname: Lee
authors.forename: Sae Jin
authors.initials: SJ
authors.lastname: Yoon
authors.forename: Sun Joo
authors.initials: SJ
authors.lastname: Kim
authors.forename: Il Kun
authors.initials: IK
authors.lastname: Chung
authors.forename: Suck Ho
authors.initials: SH
authors.lastname: Lee
authors.forename: Jeong Eun
authors.initials: JE
authors.lastname: Shin
authors.forename: Dong Soo
authors.initials: DS
authors.lastname: Lee
authors.forename: Jong Tae
authors.initials: JT
authors.lastname: Baek
authors.forename: Soon Woo
authors.initials: SW
authors.lastname: Nam
authors.forename: Sang Jeong
authors.initials: SJ
authors.lastname: Yoon
authors.forename: Seok Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: Gye Sung
authors.initials: GS
authors.lastname: Lee
authors.forename: Jong Min
authors.initials: JM
authors.lastname: Lee
authors.forename: An Na
authors.initials: AN
authors.lastname: Kim
authors.forename: Jae In
authors.initials: JI
authors.lastname: Oh
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D005260:Female; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D054328:Proton Pump Inhibitors; D006180:Proton-Translocating ATPases / Q000627:therapeutic use; D064750:Rabeprazole; D011899:Ranitidine / Q000627:therapeutic use*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D011899:Ranitidine; D006180:Proton-Translocating ATPases; D009853:Omeprazole